Erasca (ERAS) faces shareholder class action over alleged securities law violations
Hagens Berman is investigating claims of securities law violations against Erasca, Inc. (NASDAQ: ERAS) and its executives in a shareholder class action lawsuit.
The law firm Hagens Berman is investigating allegations of securities law violations against Erasca, Inc. (NASDAQ: ERAS) and its senior executives. A shareholder class action lawsuit has been initiated, claiming the company and its leadership misled investors.
The investigation centers on claims that Erasca provided misleading statements about its SYK program. Investors allege the company misrepresented the potential success and associated risks of this program, impacting their investment decisions.
Hagens Berman is seeking investors who have experienced substantial losses in Erasca stock to come forward. The firm is organizing these investors to potentially lead the class action lawsuit, aiming to recover financial damages.
Erasca is a biotechnology company focused on developing treatments for cancer. The SYK program is a key part of the company's development pipeline.